Article

<i>Ex vivo</i> drug testing in an ultra-rare sarcoma reveals therapeutic vulnerability and resistance

2022-08-04

Abstract excerpt

<h4>ABSTRACT</h4> Solitary fibrous tumors (SFTs) are rare soft tissue sarcomas for which therapeutic options are limited and ineffective. We successfully demonstrated how functional personalized treatment was implemented in the clinic for an ultra-rare sarcoma with otherwise limited options, through a combined strategy of patient-derived model development and computational drug analytics. Molecular profiling of tu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 58a457cd-31af-5e2c-a564-616cbe0cccae
DOI: 10.1101/2022.08.03.22278327

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>Ex vivo</i> drug testing in an ultra-rare sarcoma reveals therapeutic vulnerability and resistanceDOI 10.1101/2022.08.03.22278327Read

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsSemantic proximity Read

Integrated <i>ex vivo</i> screening and transcriptomic profiling to prioritize drug combinations for rare cancersSemantic proximity Read

Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcomaSemantic proximity Read

Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomasSemantic proximity Read

Establishment and characterization of a patient-derived solitary fibrous tumor/hemangiopericytoma cell line modelSemantic proximity Read

The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanibSemantic proximity Read

Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug DevelopmentSemantic proximity Read

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.Semantic proximity Read

A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients.Semantic proximity Read

Impact of tissue-agnostic approvals on management of primary brain tumors.Semantic proximity Read